
Easier, Noninvasive Diagnosis of Neurological Disorders
More companies have begun offering neurofilament light chain blood tests as a cost-effective alternative to conventional methods.
Diagnostic Testing and Emerging Technologies
LAB COMPLIANCE ADVISOR
LABORATORY INDUSTRY REPORT
NATIONAL LAB REPORTER
More companies have begun offering neurofilament light chain blood tests as a cost-effective alternative to conventional methods.
In this month’s diagnostics pipeline report, Roche gets clearance for two new Alzheimer’s early detection tests.
A recent study led by a team at the University of Gothenburg shows that multiple biomarkers could ID the disease even in people with no symptoms.
While new FDA clearances of blood-based early detection tests for Alzheimer’s represent significant progress, limitations remain.
Recent developments suggest that we are on the precipice of a new age offering expanded options for Alzheimer’s diagnosis.